GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (OTCPK:GALDY) » Definitions » Other Current Payables

GALDY (Galderma Group AG) Other Current Payables : $0 Mil (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG Other Current Payables?

Galderma Group AG's Other Current Payables for the quarter that ended in Jun. 2024 was $0 Mil.

Galderma Group AG Other Current Payables Historical Data

The historical data trend for Galderma Group AG's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG Other Current Payables Chart

Galderma Group AG Annual Data
Trend
Other Current Payables

Galderma Group AG Semi-Annual Data
Jun23 Jun24
Other Current Payables - -

Galderma Group AG Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Galderma Group AG Other Current Payables Related Terms

Thank you for viewing the detailed overview of Galderma Group AG's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.

Galderma Group AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (OTCPK:GALDY) » Definitions » Other Current Payables
Comparable Companies
Traded in Other Exchanges
GDERF:USA GALDz:UK GALD:Switzerland
Address
Zahlerweg 10, Zug, CHE, 6300
Website
https://www.galderma.com
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.